Goldman Sachs says Valeant has long road ahead, cuts rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- McKesson reports cybersecurity incident affecting its information systems
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Valeant Pharma (VRX) Adds to Gains
November 3, 2015 8:14 AM ESTBeaten down Valeant Pharma (NYSE: VRX) is adding to yesterday's gains in pre-open trade. Shares are up 5.8% to $106.28 after rising 7.15% yesterday. Shares have been under extreme pressure as short sellers point to fraud at the company and regulators point to 'price... More
Bill Ackman's Pershing Square Down 19% YTD (VRX)
November 2, 2015 9:27 PM ESTBill Ackman's Pershing Square Holdings, Ltd. released its regular monthly Net Asset Value (NAV) and Performance Report for the month of October 2015. Data showed the fund was down 7.3% during the month and is now down 19% on the year.
Much of the weakness is tied to the hedge fund's oversized... More
Dead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?
November 2, 2015 3:17 PM ESTCitron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More
